All Updates

All Updates

icon
Filter
Funding
Enveda Biosciences raises USD 55 million in Series B-2 funding to bolster pipeline
AI Drug Discovery
Jun 14, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
AI Drug Discovery

AI Drug Discovery

Jun 14, 2024

Enveda Biosciences raises USD 55 million in Series B-2 funding to bolster pipeline

Funding

  • AI-powered biotechnology company Enveda Biosciences has secured USD 55 million in a Series B2 funding round; Series B-1 in April 2023 raised USD 51 million. The round saw participation from new investors including Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy, as well as existing investors like Kinnevik and True Ventures.

  • The company intends to use the procured funds to develop its novel AI-powered platform further and to commence Phase I clinical trials for its three lead programs in late 2024 and early 2025.

  • The Colorado-based company develops novel therapeutics based on plants and natural chemistry to treat various diseases, including Wilson’s Disease, NASH, and Parkinson’s disease. Enveda’s proprietary platform, powered by machine learning and metabolomics, acts as a search engine to discover and identify novel drug candidates.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.